{"name":"Orion Corporation, Orion Pharma","slug":"orion-corporation-orion-pharma","ticker":"","exchange":"","domain":"orioncorporationorionpharma.com","description":"","hq":"Niittykumpu","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":12,"colorKey":"cardiovascular","drugs":[{"name":"11C-ORM-13070","genericName":"11C-ORM-13070","slug":"11c-orm-13070","indication":"Other","status":"phase_1"},{"name":"Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI","genericName":"Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI","slug":"bufomix-easyhaler-160-4-5-g-inhalation-dmdpi","indication":"Other","status":"marketed"},{"name":"Indacaterol maleate and glycopyrronium bromide","genericName":"Indacaterol maleate and glycopyrronium bromide","slug":"indacaterol-maleate-and-glycopyrronium-bromide","indication":"Other","status":"marketed"},{"name":"ODM-102","genericName":"ODM-102","slug":"odm-102","indication":"Other","status":"marketed"},{"name":"ODM-108 Part I","genericName":"ODM-108 Part I","slug":"odm-108-part-i","indication":"Indication under Phase 1 evaluation (not specified)","status":"discontinued"},{"name":"ODM-108 Part III","genericName":"ODM-108 Part III","slug":"odm-108-part-iii","indication":"Indication under Phase 1 evaluation (not specified)","status":"discontinued"},{"name":"ODM-203 (Period 1)","genericName":"ODM-203 (Period 1)","slug":"odm-203-period-1","indication":"Huntington's disease","status":"marketed"},{"name":"ODM-212","genericName":"ODM-212","slug":"odm-212","indication":"Other","status":"phase_1"},{"name":"Placebo Part I","genericName":"Placebo Part I","slug":"placebo-part-i","indication":"Clinical trial control / comparator (not a therapeutic indication)","status":"marketed"},{"name":"Placebo Part II","genericName":"Placebo Part II","slug":"placebo-part-ii","indication":"Other","status":"marketed"},{"name":"Stalevo","genericName":"Stalevo","slug":"stalevo","indication":"Other","status":"marketed"},{"name":"Symbicort Turbuhaler forte","genericName":"Symbicort Turbuhaler forte","slug":"symbicort-turbuhaler-forte","indication":"Other","status":"phase_1"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"neuroscience","drugs":[{"name":"Indacaterol/glycopyrronium","genericName":"Indacaterol/glycopyrronium","slug":"indacaterol-glycopyrronium","indication":"Chronic obstructive pulmonary disease (COPD) maintenance therapy","status":"marketed"},{"name":"Placebo Spiriva capsule","genericName":"Placebo Spiriva capsule","slug":"placebo-spiriva-capsule","indication":"Clinical trial control for COPD and asthma studies","status":"marketed"},{"name":"Symbicort Turbuhaler","genericName":"Symbicort Turbuhaler","slug":"symbicort-turbuhaler","indication":"Maintenance and control of asthma symptoms","status":"phase_3"},{"name":"Ventoline® Evohaler® 100 µg/inhalation pMDI","genericName":"Ventoline® Evohaler® 100 µg/inhalation pMDI","slug":"ventoline-evohaler-100-g-inhalation-pmdi","indication":"Acute relief of bronchospasm in asthma","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ODM-201 Tablet A","genericName":"ODM-201 Tablet A","slug":"odm-201-tablet-a","indication":"Castration-resistant prostate cancer (CRPC)","status":"marketed"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Comtess®","genericName":"Comtess®","slug":"comtess","indication":"Parkinson's disease (adjunctive therapy with levodopa/carbidopa to reduce motor fluctuations and 'off' periods)","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"Placebo for levosimendan","genericName":"Placebo for levosimendan","slug":"placebo-for-levosimendan","indication":"Acute heart failure","status":"phase_3"}]}],"pipeline":[{"name":"ODM-201 Tablet A","genericName":"ODM-201 Tablet A","slug":"odm-201-tablet-a","phase":"marketed","mechanism":"ODM-201 is an androgen receptor antagonist that blocks the binding of androgens to the androgen receptor, inhibiting androgen-driven prostate cancer cell growth.","indications":["Castration-resistant prostate cancer (CRPC)"],"catalyst":""},{"name":"Comtess®","genericName":"Comtess®","slug":"comtess","phase":"marketed","mechanism":"Comtess inhibits catechol-O-methyltransferase (COMT), an enzyme that breaks down levodopa, thereby prolonging levodopa's therapeutic effect in the brain.","indications":["Parkinson's disease (adjunctive therapy with levodopa/carbidopa to reduce motor fluctuations and 'off' periods)"],"catalyst":""},{"name":"11C-ORM-13070","genericName":"11C-ORM-13070","slug":"11c-orm-13070","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI","genericName":"Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI","slug":"bufomix-easyhaler-160-4-5-g-inhalation-dmdpi","phase":"marketed","mechanism":"Bufomix® Easyhaler® combines an inhaled corticosteroid (ICS) and a long-acting beta2-adrenergic agonist (LABA) to reduce inflammation and bronchodilation in the airways.","indications":[],"catalyst":""},{"name":"Indacaterol maleate and glycopyrronium bromide","genericName":"Indacaterol maleate and glycopyrronium bromide","slug":"indacaterol-maleate-and-glycopyrronium-bromide","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Indacaterol/glycopyrronium","genericName":"Indacaterol/glycopyrronium","slug":"indacaterol-glycopyrronium","phase":"marketed","mechanism":"Indacaterol is a long-acting beta-2 agonist that stimulates airway smooth muscle relaxation, while glycopyrronium is an anticholinergic that blocks muscarinic receptors to further dilate airways.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"ODM-102","genericName":"ODM-102","slug":"odm-102","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ODM-108 Part I","genericName":"ODM-108 Part I","slug":"odm-108-part-i","phase":"discontinued","mechanism":"ODM-108 Part I mechanism of action is not publicly disclosed; Phase 1 development was terminated.","indications":["Indication under Phase 1 evaluation (not specified)"],"catalyst":""},{"name":"ODM-108 Part III","genericName":"ODM-108 Part III","slug":"odm-108-part-iii","phase":"discontinued","mechanism":"ODM-108 mechanism of action is not publicly disclosed; Phase 1 evaluation focused on safety and pharmacokinetics in healthy volunteers.","indications":["Indication under Phase 1 evaluation (not specified)"],"catalyst":""},{"name":"ODM-203 (Period 1)","genericName":"ODM-203 (Period 1)","slug":"odm-203-period-1","phase":"marketed","mechanism":"ODM-203 is a selective inhibitor of phosphodiesterase 10A (PDE10A) that increases intracellular cyclic nucleotide levels in the brain.","indications":["Huntington's disease"],"catalyst":""},{"name":"ODM-212","genericName":"ODM-212","slug":"odm-212","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo Part I","genericName":"Placebo Part I","slug":"placebo-part-i","phase":"marketed","mechanism":"Placebo produces no pharmacological effect and serves as an inert control or reference standard in clinical research.","indications":["Clinical trial control / comparator (not a therapeutic indication)"],"catalyst":""},{"name":"Placebo Part II","genericName":"Placebo Part II","slug":"placebo-part-ii","phase":"marketed","mechanism":"Placebo Part II is an inert substance with no active pharmacological mechanism.","indications":[],"catalyst":""},{"name":"Placebo Spiriva capsule","genericName":"Placebo Spiriva capsule","slug":"placebo-spiriva-capsule","phase":"marketed","mechanism":"This is a placebo formulation with no active pharmacological mechanism.","indications":["Clinical trial control for COPD and asthma studies"],"catalyst":""},{"name":"Placebo for levosimendan","genericName":"Placebo for levosimendan","slug":"placebo-for-levosimendan","phase":"phase_3","mechanism":"Levosimendan is a calcium sensitizer that increases cardiac contractility without increasing oxygen demand.","indications":["Acute heart failure","Severe heart failure"],"catalyst":""},{"name":"Stalevo","genericName":"Stalevo","slug":"stalevo","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Symbicort Turbuhaler","genericName":"Symbicort Turbuhaler","slug":"symbicort-turbuhaler","phase":"phase_3","mechanism":"Symbicort Turbuhaler is a combination of budesonide, an inhaled corticosteroid, and formoterol, a long-acting beta2-adrenergic receptor agonist, used to control symptoms of asthma and chronic obstructive pulmonary disease (COPD).","indications":["Maintenance and control of asthma symptoms","Maintenance and control of symptoms in COPD"],"catalyst":""},{"name":"Symbicort Turbuhaler forte","genericName":"Symbicort Turbuhaler forte","slug":"symbicort-turbuhaler-forte","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ventoline® Evohaler® 100 µg/inhalation pMDI","genericName":"Ventoline® Evohaler® 100 µg/inhalation pMDI","slug":"ventoline-evohaler-100-g-inhalation-pmdi","phase":"marketed","mechanism":"Albuterol (salbutamol) is a short-acting beta-2 adrenergic agonist that relaxes airway smooth muscle to rapidly relieve bronchospasm and improve airflow.","indications":["Acute relief of bronchospasm in asthma","Acute relief of bronchospasm in chronic obstructive pulmonary disease (COPD)","Prevention of exercise-induced bronchospasm"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBCamZlMXdWN1JFbDlMRFJISFNNZDVoNTlwWmZ4dWNLUFRrTThLTDd3c0V3SFlNVWNuZEYybHJhLWpQanprMkFIa1ktZlRlTE13WVJr?oc=5","date":"2026-04-02","type":"pipeline","source":"Yahoo Finance UK","summary":"Orion Oyj (ORINF) stock price, news, quote and history - Yahoo Finance UK","headline":"Orion Oyj (ORINF) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwJBVV95cUxPVDY0TzVoOGg5aC0zbEMtekpqS3FydUVZd2pNbFgxV0lQX1Y4aUdhdGNMeENCdF8xNVhRdUtrblAyZzQzSF92NlBzQjItWmhkcHJDRXNmd2VhdDg5ekhvRi1BNkw1RndMeWY5MEpUTm5oSHZmTElDa3AtaFgzaTl4OW1ZT2I0NE00TUtWdExfUjRpbDNrTWNETmhBelhzRlR0YTZsYkpuVlkzc3lsanNsaWNaTHBnQk9fUmlYSlZRZVliNEJwTDR0UU1wbjJfdkc0eTV6LXdTUU5sMy1JNGVkZXkxcHRvajFOOFhnX2tkdTdHdnRuN3NEU3NuMzZBZWRISWdNNEUwX1o1azZBak55X3dvS2RvV2JfTXgxR2ZNcEZwNkM5Mm9V?oc=5","date":"2026-04-01","type":"pipeline","source":"globenewswire.com","summary":"Change in Orion Group Executive Team as of 8 April 2026 – - globenewswire.com","headline":"Change in Orion Group Executive Team as of 8 April 2026 –","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxORXd2cnAwUDFkaTRIbWpSekVlcjYwRzFyU1ZMRHBqRlVDY19OamZlbEtQaS1CTVpTZko4ZnJ2aW80SVVkeGFVd0hGd256ZFduT0VFTTc2alg1aUtvd0JwY2pvd0dqXzBSWTlraWJQakVjNmxIWEQ2NXdWQUl0VDMxRVI0OGM0RV9BUjg1QzVGUkE4WTVJQUNBRmMtY3BDQ1o5NFpOZnc5eXB6XzBzSHozNmJ1cGl3VmQwUUE3emEyY3ZuaXR3NUZCMTdRU2o5akZqb3dXMFRZcEFNZ25jMS1iX1hSUHd6bTRVaFJJOG13RGw1NTctYklHdU9mQ1RzVTQ?oc=5","date":"2026-03-31","type":"pipeline","source":"globenewswire.com","summary":"Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) - globenewswire.com","headline":"Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAJBVV95cUxOaXVMYm52NTlYTUthYk8xak01WFZfWGE1ajAyQlNrQ0tvS2xDTmFGNmRUOXhybkZaYUVYSVUwM2NvWWRuenlhZTlBQ1V6c01SNlBDUlpJeEhlMTBpb0x6RlVXcmJ1eTBvNWpqTC1RNW9CeXRaZ3ZOMkVlVWRsUEVmY1ZwSXJTRlNINDgtbWp4Wi1qUXlYT0dwTGJMeEpURE10YXZYaU9FQkU3bmw2alNpYnJ3S095eFpUVnZNYzEyUVpLVTZSOTRiR3BZN0xxYk9pdTBfRm11TndDYnlBYmxyYXBlLTJJZXNod2xfeWFPSlNKNERIUUhnbTFYNE1JV1JlYTRhaUtQS1BRZlp4Y0FwNm9feW9KeHRIY0Q0Tw?oc=5","date":"2026-03-24","type":"pipeline","source":"globenewswire.com","summary":"Decisions taken by Orion Corporation's Annual General - globenewswire.com","headline":"Decisions taken by Orion Corporation's Annual General","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQand1WlZfMmhYS0NCbzVmXzFMX041a1dYOUJCdWtyZGVQTEt2eFZQa0xQSGZFSlV1T1VSOUNReml0WHlCaGxneHpDU1gxa0YtUmgxQUtOeTF0ZWk0Q3NIeFZUb3pXMGZyaGpZQzN6V3RFS0FMWVJxdGVtNURDVGNveFFkWTFUaldnaklUXy1YTTVFY0lYYnc?oc=5","date":"2026-03-19","type":"pipeline","source":"Yahoo Finance UK","summary":"Orion Corporation: Managers’ transactions – Outi Vaarala - Yahoo Finance UK","headline":"Orion Corporation: Managers’ transactions – Outi Vaarala","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxPT3lEb1cyNENHbUVmdHhwQi1Qbi1IRS1JeC1iS3Y2T1NIN0pMRE1aM2k4dENfWjJIOFFPSWxMbno1Y0J6b2ZRMldjeGdYLXE0TU1QZFlBSTlVSk5kaWs3bWE1bUd1SmQ0SjVYOENHNmRKU3djQXVjaXVtck1sUTdmXw?oc=5","date":"2026-03-18","type":"deal","source":"Yahoo Finance UK","summary":"Peace through well-being: Orion and CMI - Martti Ahtisaari Peace Foundation announce partnership - Yahoo Finance UK","headline":"Peace through well-being: Orion and CMI - Martti Ahtisaari Peace Foundation announce partnership","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPaS0xbHUxQ01mZUxUR1FFbDVsMGRCOWhUUkxxeHpIZmxxSmRGNFAtSUpucEhITGhXd2N5Ym5jbml0MlR1RXp5QUNyb3dsTjVzX2wxVVBaLWdXY2NoM3dMVkhZazdtUENwYl9iaGhPZGMtNS1qOHh3UlFMaW9IcEJ1RUVWS2JVZUJOSmlfZUVpSUhlZkxk?oc=5","date":"2026-03-10","type":"pipeline","source":"finance.yahoo.com","summary":"Orion Corporation: Managers’ transactions – Outi Vaarala - finance.yahoo.com","headline":"Orion Corporation: Managers’ transactions – Outi Vaarala","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxNSjFXYWNhdTJraHVCdzYtb1RaLWFEaGRIZm85RUlwNjlTdW1LMEJmWnY0OThfdm1tc0hrbGtLWWIwdGJjbXhvUHotTWh5dGZYRm5OZDk3YkpZeVk0RmNoamNQX1pHZW42VjFFaTFEanloZmR1MTN3LXZDWnBVLU1qOHlQcV9MRHkzUmR4eUN2VXdra3ByNnVWM2YxekdtRHlQdVYza29RVU9RM3VOWEhVdi1VRmF4Rm9UN19HV2o1SjFqdU55MVo0dG0tdFZhb1RTNjc4MDRB?oc=5","date":"2026-03-10","type":"pipeline","source":"globenewswire.com","summary":"Orion Corporation: Transfer of 172,778 own B shares on 10 March 2026 - globenewswire.com","headline":"Orion Corporation: Transfer of 172,778 own B shares on 10 March 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxPMXg0UkZlVGlTbDJOUU00bkF4T3cxeDRIV1ZwQWJLaTM4QVFidHEzdi1QY2pjNnJmYlNjbFVtUG8yal90aEJZV2VmMWo1TVljVHNjSk0zbTNSRzBKd2VjZHRxYlhiM3lCdGsyREh6MjA3LTZ1WXd0ME8zSkYzUk9JU3BpdDQ0UktlTzhHLXRlTjlraFUwSEs5VEpwM0FDbXdGLUhTVkdJcVh2Z2czcE1lSC1FX0pJZnFYMTdFMXl4QzR5UmpjekIwc2hDQjBVZ1haQlJzekNZZVlWMzE2V2NTT3NNU1U5bUk?oc=5","date":"2026-02-27","type":"pipeline","source":"globenewswire.com","summary":"Orion Group Financial Statement documents 2025 and Remuneration Report published - globenewswire.com","headline":"Orion Group Financial Statement documents 2025 and Remuneration Report published","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxQNlVnUDcyaUtWMHFLWkxFSXZkQUFqaUhoaTd2YnhDaFBKbGs0U2lWVHp0SE45SkFoWDl0UklqZUVzaXdFYzBNd1ktNXE0clRmZXV6VFl5ZXNMVUlOczZLRkVxSnExdk1uRkxmZVlweF9laUhxY3BrYXVoOVQzUDdXaDNyNm1hUV92Q3hxMks3NkFLU2hmZ0NheWxRR0VJUDM5WjZvYW5xaC1KcHVOVU9uUENUMmNGOXhPeWFlN0o2Ti14N0pGUlBmWg?oc=5","date":"2026-02-03","type":"pipeline","source":"globenewswire.com","summary":"62,752 Orion Corporation A shares converted into B shares - globenewswire.com","headline":"62,752 Orion Corporation A shares converted into B shares","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxNQnRyRmZJTDFWa1plWjJnbUFDaWl1WnVzUzNGbkQ2UkMtejFpOV9PQWpxcjk2TUdaa2NPeFZ6dXlIRE93NlRqYXpsUk8xek8wYW9qWkQtbE5UMUNPTHBNMV9IUFlUZVpDNlIxcEdjQi1waEVHVVV1QnkxNjdvZ1lxSGl4MFo2M0Y0SzRubnN5Q08?oc=5","date":"2026-01-13","type":"pipeline","source":"finance.yahoo.com","summary":"Inside information: Orion provides outlook for 2026 and estimates that the annual Nubeqa® net sales recorded by Orion has potential to exceed EUR 1 billion in the future - finance.yahoo.com","headline":"Inside information: Orion provides outlook for 2026 and estimates that the annual Nubeqa® net sales recorded by Orion ha","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxPN3hzbUtoMVMzalFleC05QW5ySmt4M2EwSXFqWWVnWlI0dkRFZURrUFNXdHRfa0FaYlRGZWp4cnNUMFMyWDhTbFhKMUt6VEVJTTB5MmFTZHoxMElUSGhmckRhdWE2OGJkZWFLUXpJSFNmZ2pNSWh2eGktVk1KcDFkV2hfbkI3UDdleFE?oc=5","date":"2025-12-02","type":"pipeline","source":"finance.yahoo.com","summary":"Inside information: Orion to receive EUR 180 million milestone and updates full-year outlook for 2025 - finance.yahoo.com","headline":"Inside information: Orion to receive EUR 180 million milestone and updates full-year outlook for 2025","sentiment":"neutral"}],"patents":[],"drugCount":19,"phaseCounts":{"marketed":12,"phase_1":3,"discontinued":2,"phase_3":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}